Prognostic Value of Long Noncoding RNA SNHG11 in Patients with Prostate Cancer

Horm Metab Res 2022; 54: 187-193 DOI: 10.1055/a-1745-8952The present study was aimed to explore the prognostic value of long noncoding RNA
SNHG11 in prostate cancer, study its expression, and assess its effect on tumor
progression. One hundred and twenty prostate cancer patients and 45 cases of
benign prostate hyperplasia (BPH) patients were collected. RT-qPCR was used to
test the expression of SNHG11 in prostate cancer and BPH tissues, as well as in
cell lines. Kaplan-Meier survival analysis and Cox regression assays were
introduced to evaluate the prognostic meaning of SNHG11 in prostate cancer. The
CCK-8 assays were performed to explore the effect of SNHG11 on prostate cancer
cell proliferation, and a Transwell assay was conducted to access the influence
of SNHG11 on prostate cancer cell migration and invasion. SNHG11 expression
level was upregulated both in prostate cancer tissues and cell lines.
Overexpression of SNHG11 was significantly associated with Gleason score,
clinical T stage, surgical margin status, and lymph node metastasis. Patients
with high SNHG11 expression levels led to a shorter overall survival time and
biochemical recurrence-free survival when compared with those of low expression
levels. Multivariate Cox regression results suggested that SNHG11 has the
potential to act as a prognostic marker fo...

Source: Hormone and Metabolic Research - March 11, 2022 Category: Endocrinology Authors: Li, Ying Pan, Bin Guo, Xiuqin Meng, Xiaomin Tian, Xiaojing Tags: Endocrine Care Source Type: research